Overview
α-synucleinopathies encompass neurodegenerative disorders characterized by the accumulation of α-synuclein protein, including Parkinson's disease, multiple system atrophy, and dementia with Lewy bodies. Cardiovascular autonomic failure is a significant feature impacting quality of life and prognosis in these conditions 1.Diagnosis
Presence of characteristic motor symptoms or cognitive impairments specific to the α-synucleinopathy subtype.
Assessment of cardiovascular autonomic function using tests like heart rate variability analysis, tilt table tests, and blood pressure monitoring 1.
Neuroimaging may reveal white matter hyperintensities and altered cerebral perfusion patterns 1.Management
First-line treatments: Addressing autonomic symptoms with medications such as fludrocortisone for orthostatic hypotension 1.
Adjunctive therapies: Cognitive rehabilitation and physical therapy to manage cognitive dysfunction and motor symptoms 1.
Supportive care: Regular monitoring of cardiovascular health and cognitive functions to manage disease progression 1.Special Populations
Elderly: Increased focus on managing cardiovascular autonomic failure due to its significant impact on daily activities and mortality 1.
Comorbidities: Close monitoring and tailored management of coexisting conditions that may exacerbate autonomic dysfunction 1.Key Recommendations
Screen for cardiovascular autonomic failure early in the course of α-synucleinopathies to identify patients at risk for worse outcomes (Evidence: Moderate 1).
Implement therapeutic interventions targeting cardiovascular autonomic failure to potentially improve quality of life and prognosis (Evidence: Moderate 1).
Regularly assess cognitive functions and cerebral perfusion in patients with neurocardiovascular instability (Evidence: Moderate 1).References
1 Fanciulli A, Strano S, Colosimo C, Caltagirone C, Spalletta G, Pontieri FE. The potential prognostic role of cardiovascular autonomic failure in α-synucleinopathies. European journal of neurology 2013. link